Several companies, including Boston Scientific and Corindus Vascular Robotics, have released details of their presentations at the upcoming 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA).

Ancora Heart

  • 25 September (Wednesday); 4.35pm; Room 203
    Abstract: Hypertension and heart failure therapies (session II) heart failure therapies, TCT 88—six-month outcomes of an early feasibility study of the AccuCinch left ventricular repair system in patients with heart failure and functional mitral regurgitation.
  • 27 September (Friday); 5.24pm; Room 155/157
    Transcatheter mitral valve repair—beyond the MitraClip (session III)—emerging TMVR devices; part 2; annuloplasty and others, basal ventriculoplasty: ancora device description results and ongoing studies
  • 28 September (Saturday); 5.30pm; Room 156/158
    Interventional heart failure and haemodynamic support—chronic therapies–device-based therapies for chronic heart failure, ventricular reshaping for HF: ANCORA

Boston Scientific

  •  25 September (Wednesday); 3.45pm; room 209–210Abstract: Lotus aortic valve system—mid-term outcomes after transcatheter aortic valve replacement with a mechanically-expanded versus self-expandable valve: three-year results from the REPRISE III randomised trial.
  • 26 September (Thursday); 12.15pm; Main Arena 1
    Late-breaking trial: Synergy BP stent—primary outcomes of the evolve short DAPT study evaluating 3-month dual antiplatelet therapy in high bleeding risk patients treated with the synergy everolimus-eluting, bioabsorbable polymer-coated coronary stent.

Corindus Vascular Robotics

  • 27 September (Friday); 6.45–7.45am; Room 216
    Breakfast symposium—Transforming robotics into an advanced clinical tool through automation and remote capabilities.


  • 26 September (Thursday); breakfast symposium—Supersaturated oxygen in STEMI to reduce infarct size–a new FDA approved therapy.
  • 26 September (Thursday); poster—one year outcomes of supersaturated oxygen therapy in acute anterior myocardial infarction (the IC HOT Study); 2pm; Hall D.
  • 26 September (Thursday); SSO2 Therapy: STEMI Case Studies; 2pm; Hall D.
  • 26 September (Thursday); infarct size reduction—from the first FDA approved therapy SSO2 to novel approach; 4.35pm; Room 151/153.